Bicara Therapeutics Inc. Common Stock logo BCAX - Bicara Therapeutics Inc. Common Stock

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 5
HOLD 2
SELL 0
STRONG
SELL 0
| PRICE TARGET: $32.33 DETAILS
HIGH: $42.00
LOW: $18.00
MEDIAN: $37.00
CONSENSUS: $32.33
UPSIDE: 20.28%

Stock News

Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors

Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors

BOSTON, July 28, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the appointments of Jeremy Bender, Ph.D., MBA and Christy Oliger to its Board of Directors. Dr. Bender, who most recently served as Chief Executive Officer at Day One Biopharmaceuticals through its acquisition by Servier in 2026, brings more than 20 years of corporate strategy and operating experience in biotechnology to Bicara. Ms. Oliger brings more than 30 years of commercial and operating experience in global biopharmaceutical organizations, having most recently served as Senior Vice President of the Oncology Business Unit at Genentech.

Jul 28, 2026 04:30 AM • globenewswire.com
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded inducement grants on July 1, 2026 to four new employees under Bicara's 2026 Inducement Plan as a material inducement to employment. The employees received, in the aggregate, non-qualified stock options to purchase 191,425 shares of Bicara's common stock, par value $0.0001 per share, with an exercise price of $28.91 per share, equal to the closing price of Bicara's common stock as reported by Nasdaq on July 1, 2026.

Jul 02, 2026 04:30 AM • globenewswire.com
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that, effective May 8, 2026, it awarded an inducement grant to Christopher Sarchi under Bicara's 2026 Inducement Plan as a material inducement to his commencement of employment as Bicara's Chief Commercial Officer.

May 13, 2026 04:30 AM • globenewswire.com
Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET

Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it will report first quarter 2026 financial results and business updates before the market opens on Monday, May 11, 2026. Bicara will host a conference call to discuss the financial results and business updates at 8:30 a.m. ET the same day. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and a unique PIN that will allow them to access the call. To access the live webcast, please visit the “Events & Presentations” section within the Investors page on the Bicara website. A replay of the webcast will be available for 30 days following the event.

May 04, 2026 04:30 AM • globenewswire.com
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded an inducement grant on April 1, 2026 to one new employee under Bicara's 2026 Inducement Plan as a material inducement to employment.

Apr 03, 2026 04:30 AM • globenewswire.com
Bicara: Maintaining 'Buy' Rating On Ficerafusp Alfa Phase 3 Advancement

Bicara: Maintaining 'Buy' Rating On Ficerafusp Alfa Phase 3 Advancement

Bicara Therapeutics Inc. maintains a Buy rating, driven by progress in its pivotal phase 3 FORTIFI-HN01 study for 1st-line R/M HPV-negative HNSCC. BCAX's ficerafusp alfa plus KEYTRUDA achieved a 12-month OS of 61% and a confirmed ORR of 54% in phase 1/1b, supporting continued development. Key upcoming catalysts for BCAX include phase 3 interim data in mid-2027 and long-term phase 1b follow-up at ASCO 2026, with near-full enrollment expected by year-end.

Mar 31, 2026 11:34 AM • seekingalpha.com

Price Targets